Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 in Adults With Moderate-to-severe T2-high Asthma Who Are Partially Controlled on Inhaled Corticosteroid and Long-acting Beta 2 Agonist Therapy

NCT05935332 is registered in ClinicalTrials.gov with RAPT Therapeutics, Inc. as lead sponsor.

NCT NCT05935332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05935332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 in Adults With Moderate-to-severe T2-high Asthma Who Are Partially Controlled on Inhaled Corticosteroid and Long-acting Beta 2 Agonist Therapy
Lead sponsor
RAPT Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 5, 2023
Completion date
June 21, 2024
Enrollment
38 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

asthma